Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.3K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.3K
Spare Receptors01:30

Spare Receptors

4.7K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.7K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.9K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Oncogene·2006
Same author

Renal anemia aggravated by long-term parvovirus B19 and cytomegalovirus infection in a renal transplant patient: case report and evaluation of B19 seroprevalence in dialysis patients.

Transplantation proceedings·2006
Same author

Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.

Xenobiotica; the fate of foreign compounds in biological systems·2005
Same author

Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes.

Leukemia·2005
Same author

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

Bone marrow transplantation·2005
Same author

The expression of Ca 15-3 in the male breast cancer tumor cells and in the serum.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie·2005

Related Experiment Video

Updated: Feb 28, 2026

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

2.2K

The receptor super-antagonist Sant7.

R Savino1, A Demartis, L Ciapponi

  • 1IRBM,I-00040 POMEZIA,ROME,ITALY. IRCCS,IDI,BIOCHEM LAB,ROME,ITALY. UNIV AQUILA,I-67100 LAQUILA,ITALY. CNRS,INST MOL GENET,F-34033 MONTPELLIER 1,FRANCE.

Oncology Reports
|May 19, 2011
PubMed
Summary

Interleukin-6 (IL-6) is crucial in multiple myeloma. New IL-6 receptor antagonists, particularly Sant7, effectively inhibit myeloma cell growth and induce apoptosis, showing promise for immunotherapy.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K

Related Experiment Videos

Last Updated: Feb 28, 2026

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

2.2K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Interleukin-6 (IL-6) is a key driver of multiple myeloma (MM) pathogenesis, promoting cancer cell growth and survival.
  • IL-6 interacts with its receptor complex, involving IL-6R alpha and gp130 signaling chains, through three distinct binding sites.
  • Targeting the IL-6 receptor offers a potential therapeutic strategy for multiple myeloma.

Purpose of the Study:

  • To develop and evaluate novel IL-6 receptor antagonists with specific binding site modifications.
  • To assess the efficacy of these antagonists in inhibiting the growth of IL-6-dependent multiple myeloma cell lines.
  • To investigate the pro-apoptotic effects and signaling blockade capabilities of the developed antagonists.

Main Methods:

  • Generation of IL-6 receptor antagonists with substitutions at binding sites 1, 2, and/or 3.
  • Testing antagonist efficacy on a panel of IL-6-dependent human myeloma cell lines (XG-1, XG-2, XG-4, XG-6).
  • Assessing the pro-apoptotic capacity and intracellular signaling inhibition by the antagonists.

Main Results:

  • Site 2+3 antagonist Sant7 demonstrated broad efficacy, inhibiting all tested myeloma cell lines.
  • IL-6 receptor antagonists exhibited pro-apoptotic activity in myeloma cells.
  • Sant7 was the most potent apoptosis inducer and counteracted endogenous IL-6 effects.

Conclusions:

  • The IL-6 receptor antagonist Sant7 shows significant potential as a therapeutic agent for multiple myeloma immunotherapy.
  • Targeting specific IL-6 binding sites offers a viable strategy for developing novel anti-myeloma therapies.
  • Sant7's dual action of growth inhibition and apoptosis induction highlights its therapeutic promise.